Screener
King Pharmaceuticals KG Interest and amortization expenses
Interest and amortization expenses at other companies
Other financials
Where this comes from
Reported directly by King Pharmaceuticals in its filing.
Tagged under the XBRL concept kg:InterestAndAmortizationExpensesNet.
The source filing: King Pharmaceuticals’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 8:49 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-054606
| Line item | For the Three Months Ended June 30, 2026 | For the Three Months Ended June 30, 2025 | For the Six Months Ended June 30, 2026 | For the Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Net loss and loss adjustment expenses | 1,515 | (5,961) | 3,770 | (5,961) |
| Commission and other acquisition expenses | 983 | 394 | 2,456 | 394 |
| General and administrative expenses | 10,493 | 5,493 | 22,737 | 6,636 |
| Interest and amortization expenses | 4,177 | 1,519 | 8,073 | 1,519 |
| Change in fair value of earn out liability | — | 2,679 | — | 2,679 |
| Gain on bargain purchase | — | (73,590) | — | (73,590) |
| Foreign exchange and other (gains) losses | (2,278) | 5,102 | (4,498) | 5,102 |
| Total expenses | 14,890 | (64,364) | 32,538 | (63,221) |
Item 1. Financial Statements
FAQ
- What is King Pharmaceuticals's interest and amortization expenses?
- King Pharmaceuticals (KG) reported interest and amortization expenses of $4.18M in Q2 2026.
- How has King Pharmaceuticals's interest and amortization expenses changed year-over-year?
- King Pharmaceuticals's interest and amortization expenses increased by 175.0% year-over-year, from $1.52M to $4.18M.
- What does interest and amortization expenses mean?
- Interest and amortization expenses as reported by Kestrel Group Ltd.
Ask your AI about King Pharmaceuticals's interest and amortization expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude